| Date | Title | Description | |
|---|---|---|---|
| 26 Jun 2024 | On corporate transactions | ROVI notes the recent press speculation and informs about the assessment of potential strategic alternatives | Download |
| 24 Jun 2024 | On business and financial situation | ROVI publishes the press release in relation to information and guidance on its strategic plan for expansion and growth | Download |
| 08 May 2024 | On P&L | The Company releases the press release related to the first three months of 2024 financial results | Download |
| 08 May 2024 | On P&L | The Company releases the first three months 2024 financial results presentation | Download |
| 25 Apr 2024 | On business and financial situation | ROVI announces agreement to manufacture pre-filled syringes | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 26 Apr 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 19 April and 25 April 2024 | Download |
| 19 Apr 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 12 April and 18 April 2024 | Download |
| 12 Apr 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 5 April and 11 April 2024 | Download |
| 05 Apr 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 28 March and 4 April 2024 | Download |
| 02 Apr 2024 | On business and financial situation | ROVI informs on the FDA’s approval of Risvan® as a treatment for schizophrenia | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 05 Oct 2017 | Contratos de liquidez y contrapartida | Liquidity contract: modification of transactions conducted from 11 July to 30 September 2017. | Download |
| 03 Oct 2017 | Contratos de liquidez y contrapartida | Liquidity contract: transactions conducted from 11 July to 30 September 2017 | Download |
| 07 Sep 2017 | Otros sobre negocio y situación financiera | The Company informs that commences the enoxaparin biosimilar marketing in Germany | Download |
| 26 Jul 2017 | Información sobre resultados | ROVI releases the presentation related to the 2017 first half results | Download |
| 26 Jul 2017 | Información sobre resultados | ROVI releases the presentation related to the 2017 first half results | Download |